

Alexandra Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1927146/publications.pdf>

Version: 2024-02-01

38
papers

981
citations

567281

15
h-index

454955

30
g-index

38
all docs

38
docs citations

38
times ranked

1471
citing authors

#	ARTICLE	IF	CITATIONS
1	Late Recurrence Following Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1400-1406.	1.6	9
2	Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2â†’CNTF axis to promote progression of brain metastases. <i>Cancer Letters</i> , 2022, 540, 215726.	7.2	24
3	Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	32
4	On the Road to Precision: Understanding the Biology Driving Genomic Assays. <i>Journal of Clinical Oncology</i> , 2021, 39, 100-102.	1.6	5
5	Diabetes, Obesity, and Inflammation: Impact on Clinical and Radiographic Features of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2757.	4.1	17
6	TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers. <i>Cancers</i> , 2021, 13, 2340.	3.7	5
7	A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes. <i>Clinical Cancer Research</i> , 2021, 27, 4486-4490.	7.0	7
8	Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. <i>Cancer Cell</i> , 2021, 39, 989-998.e5.	16.8	131
9	Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab071.	2.9	6
10	Abstract 2866: Truncated glioma-associated oncogene homolog 1 (tGLI1) is an actionable therapeutic target in breast cancer brain metastases. , 2021, , .		0
11	Abstract 1979: JAK2/STAT3 and TrkA pathways are frequently co-activated in triple-negative and HER2-enriched breast cancers and the co-activation correlates with an increased potential of metastasis. , 2021, , .		0
12	Epidemiology of De Novo Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 302-308.	2.4	38
13	Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC. <i>Clinical Cancer Research</i> , 2021, 27, 5810-5817.	7.0	19
14	BSCI-14. tGLI1 is an actionable therapeutic target in breast cancer brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, iii4-iii4.	0.7	0
15	Developing a biomechanical model-based elasticity imaging method for assessing hormone receptor positive breast cancer treatment-related myocardial stiffness changes. <i>Journal of Medical Imaging</i> , 2021, 8, 056002.	1.5	4
16	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptorâ€“Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3171-3181.	1.6	54
17	616â€…CD47 blockade modulates immunosuppressive checkpoint molecules and cellular metabolism to sensitize triple-negative breast cancer tumors to immune checkpoint blockade therapy. , 2021, 9, A646-A646.		1
18	Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 667397.	2.8	11

#	ARTICLE	IF	CITATIONS
19	54. tGLI1 IS AN ACTIONABLE THERAPEUTIC TARGET IN BREAST CANCER BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii11-ii11.	0.7	0
20	Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis. <i>Oncogene</i> , 2020, 39, 6589-6605.	5.9	50
21	Whatâ€™s the Price? Toxicities of Targeted Therapies in Breast Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 55-70.	3.8	13
22	Effect at One Year of Adjuvant Trastuzumab for HER2+ Breast Cancer Combined with Radiation or an Anthracycline on Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2020, 125, 1906-1912.	1.6	0
23	Neuromuscular ultrasound for taxane peripheral neuropathy in breast cancer. <i>Muscle and Nerve</i> , 2020, 61, 587-594.	2.2	12
24	Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016. <i>Clinical Breast Cancer</i> , 2020, 20, e410-e422.	2.4	8
25	Incidence and Survival Among Young Women With Stage I-III Breast Cancer: SEER 2000-2015. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz040.	2.9	53
26	Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF. <i>EBioMedicine</i> , 2019, 44, 194-208.	6.1	45
27	Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014. <i>Oncologist</i> , 2018, 23, 481-488.	3.7	77
28	Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 144-149.	2.4	10
29	Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis. <i>Journal of Thoracic Disease</i> , 2018, 10, 5850-5859.	1.4	17
30	Frequency of Transition From Stage A to Stage B Heart Failure After Initiating Potentially Cardiotoxic Chemotherapy. <i>JACC: Heart Failure</i> , 2018, 6, 1023-1032.	4.1	15
31	Use of non-ionizing electromagnetic fields for the treatment of cancer. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 284-297.	3.0	22
32	Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. <i>Biomaterials</i> , 2018, 182, 114-126.	11.4	44
33	Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1490854.	4.6	200
34	Applying dynamic contrast enhanced MSOT imaging to intratumoral pharmacokinetic modeling. <i>Photoacoustics</i> , 2018, 11, 28-35.	7.8	11
35	Neuromuscular ultrasound for assessment of peripheral neuropathy in breast cancer patients receiving taxane therapy. <i>Journal of Clinical Oncology</i> , 2018, 36, e22083-e22083.	1.6	1
36	Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. <i>Journal of Radiosurgery and SBRT</i> , 2018, 5, 277-283.	0.2	5

#	ARTICLE	IF	CITATIONS
37	Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. <i>Journal of Hematology and Oncology</i> , 2017, 10, 100.	17.0	28
38	Male Breast Cancer as a Second Primary Cancer: Increased Risk Following Lymphoma. <i>Oncologist</i> , 2017, 22, 895-900.	3.7	7